This communication reports the development and performance assessment of a rapid diagnostic test for identifying horses actively infected with the neurovirulent pathotype of equine herpesvirus-1 (EHV-1). The test is a real-time polymerase chain reaction (PCR)-based assay that uses EHV-1 pathotype-specific TaqManH reporter probes for discrimination between neuropathogenic and non-neuropathogenic strains of EHV-1 in equine blood or nasal swabs. The diagnostic performance of the new technique was evaluated by testing specimens collected from 234 horses involved in recent outbreaks of EHV-1 myeloencephalopathy at three separate thoroughbred racetracks and one large riding/boarding stable. Side-by-side comparison of the EHV-1 pathotyping results yielded by the new single-step, PCR-based allelic discrimination technique (24-hour turn-around-time) with those generated by a multi-step, conventional nested PCR followed by nucleotide sequencing of the amplified DNA (4-day turn-around-time) revealed complete agreement between the 2 test methods. The ability to rapidly identify horses infected with neuropathogenic strains of EHV-1 using a single-step, PCR-based method has significant implications for future diagnostic evaluation of suspect animals.
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The recent upsurge in the number of large, highmortality outbreaks of equine herpesvirus-1 (EHV-1) neurological disease poses an emerging threat to equine health and to the economic prosperity of horse-related businesses. [2] [3] [4] [7] [8] [9] Rapid, laboratory-based diagnosis of the disease is important for prompt implementation of infection-control measures designed to minimize transmission of the virus to other horses at the outbreak site.
Recent experimental studies have identified a single nucleotide polymorphism (SNP) within the EHV-1 gene encoding the viral DNA polymerase (open reading frame-30 [ORF30]) that is highly associated (P {LT} 0.0001) with the viral attribute of neuropathogenicity for horses. 6 Of the 32 investigated outbreaks of EHV-1 neurological disease that occurred in the United States and the United Kingdom between 2001 and 2006, 30 (94%) were caused by the ORF30 mutant strain of EHV-1 (G. Allen and N. Davis-Poynter, unpublished data). The only method currently available for identification of isolates of EHV-1 as either mutant (ORF30 G 2254 ) or wild type (ORF30 A 2254 ) is the specialized, time-consuming technique of nucleotide sequence determination at the identified polymorphic site of the viral genome. 1 Because of multiple obstacles to the adaptability of DNA sequencing to the high throughput environment of veterinary diagnostic laboratories, there remains an urgent need for a more practical test for rapid identification of horses actively infected with mutant, neuropathogenic strains of EHV-1.
The objective of this study was to address this unmet diagnostic need by developing a rapid, inexpensive, and diagnostic laboratory-friendly method for identification of the SNP genetic marker that distinguishes neuropathogenic from nonneuropathogenic strains of EHV-1. The technique for rapid SNP discrimination using real-time PCR and allele-specific TaqManH detection probes was first described in 1995. 5 The technique is a duplexed, end-point PCR assay that detects sequence variants at a single SNP site in a target DNA fragment. A pair of uniquely labeled TaqMan fluorescent probes are used, one a perfect match to the wild-type DNA sequence and the other a perfect match to the mutated sequence. The assay measures and compares the level of fluorescence associated with hybridization of the 2 TaqMan detection probes to the amplified target DNA at the end of PCR amplification.
Such an allelic discrimination, real-time PCR assay was developed for simultaneous detection and pathotype identification of EHV-1 DNA in nasal secretions or the buffy coat fraction of venous blood collected from horses. Oligonucleotide primers for amplification were designed to be specific for EHV-1 and to amplify a 145-bp ORF30 gene fragment that encompasses the site of the mutation (ORF30 A 2254 R G) highly associated with neuropathogenic strains of EHV-1 6 ( Table 1) . Two EHV-1 pathotypespecific TaqMan detector probes were synthesized and labeled with separate fluorescent dyes, VIC a and 6-FAM a Figure 1 . Illustration of ability of described real-time PCR assay to detect EHV-1 DNA in diagnostic equine specimens and to discriminate between ORF30 A 2254 wild type and ORF30 G 2254 mutant strains of the virus. Shown are real-time PCR amplification plots for EHV-1 DNA isolated from blood leukocytes of 3 horses infected with neuropathotype strains (panel A) or with nonneuropathotype strains (panel B) of the herpesvirus. Each of the 6 pairs of near-overlapping lines corresponds to the reporter fluorescence level of ( 3) with 900 nmol/l each of forward and reverse amplification primers and 200 nmol/l each of the 2 pathotype-specific, fluorescent TaqMan probes. Reaction mixtures containing nontemplate water controls, DNA from known neuropathotype or nonneuropathotype EHV-1 isolates (positive controls), and EHV-4 DNA (specificity control) were included in each amplification run. The PCR assay was performed in 96-well plates in an ABI 7500 fast real-time PCR system. a Amplification parameters consisted of an initial denaturation step of 95uC for 10 minutes followed by 55 cycles of 95uC for 15 seconds and 65uC for 1 minute. The time requirement for completing the test, from initial receipt of a diagnostic specimen to the generation of reportable results, was approximately 8 hours.
Post-run analysis for detection and pathotype identification of EHV-1 DNA present in each test sample was performed by the ABI 7500 SDS allelic discrimination analysis software (version 1.3.1). a Amplification in real time of each genotype of EHV-1 DNA (wild type or neurologic mutant) present in the samples test wells is exhibited by the software as a plot of PCR cycle number versus accumulated level of fluorescence (R n ) from each of the 2 TaqMan reporter probes (Fig. 1) . Results of the PCR assay for client reporting and archival storage are outputted by the analysis software as a spreadsheet that provides information, for each sample tested, on test results of the control wells, presence or absence of detectable EHV-1 DNA in the sample, and the neuropathic genotype of any EHV-1 strain detected.
The diagnostic performance (i.e., sensitivity and specificity) of the real-time allelic discrimination PCR test was assessed in regard to both 1) detection of EHV-1 infection in horses, and 2) identification of the infecting EHV-1 strain as possessing either the neuropathogenic or nonneuropathogenic genotype. Evaluation of the assay was performed by the testing of samples submitted from horses involved in 4 recent outbreaks of EHV-1 neurological disease. The study sample of animals consisted of 234 adult horses (196 Thoroughbred and 38 miscellaneous breed horses) known to have been exposed to EHV-1 during large myeloencephalopathy epizootics that occurred between 2003 and 2006 at three thoroughbred race tracks and a large boarding/riding establishment located in the United States.
Total DNA was isolated from submitted equine nasal swabs and/or the leukocyte fraction of submitted EDTAblood samples by 1) binding to glass fiber-containing spin tubes in the presence of a chaotropic salt, b or 2) the sequential-step isolation technique of cell lysis, salt precipitation of proteins, and isopropanol precipitation of DNA, c respectively. The DNA concentrations in the sample preparations were determined by measuring the spectrophotometric absorbance at 260 nm, and 1-mg DNA samples were tested in duplicate by both 1) the real-time PCR assay described herein, and 2) by conventional nested PCR followed by nucleotide sequence determination of the amplified ORF30 DNA fragment. 1 The test results generated by the 2 diagnostic formats were compared and used to calculate the relative sensitivity and specificity of the new real-time PCR assay, using the conventional nested PCR/DNA sequencing test as the reference test for comparison ( Table 2 ). Relative to the performance of r duplicate amplification reactions run for each horse. Hybridization to PCR-amplified EHV-1 DNA by ORF30 A 2254 (wild type)-and ORF30 G 2254 (mutant)-specific TaqManH reporter probes are denoted by blue and green lines, respectively. conventional nested PCR, the sensitivity and specificity of the real-time PCR assay for detection of EHV-1 infected horses were 96.3% and 100%, respectively. When compared with DNA sequencing, the sensitivity and specificity of the real-time PCR assay for identification of the neuropathic genotype present in EHV-1 positive horses were both 100%. The assessment verified real-time allelic discrimination PCR as a rapid, sensitive and specific diagnostic tool for use in simultaneously detecting the presence of EHV-1 DNA in equine clinical specimens and, without additional steps, for identifying the neuropathic genotype of the infecting EHV-1 strain. Importantly, the new test allowed detection of simultaneous co-circulation of both EHV-1 pathotypes within the same outbreak ( Table 2 ). In such cases, only horses infected with mutated strains of EHV-1 developed neurological disease. A carefully worded laboratory reporting of the meaning of the new assay results will be important for avoiding their unjustified over-interpretation by veterinary clientele; e.g., ''relative to infection of a horse by ORF30 A 2254 wild-type strains of EHV-1, infection by ORF30 G 2254 mutant virus strains carries a greater risk for development of neurologic complications.'' 
